A Phase 3 interventional study of Extended Release Buprenorphine in Opioid Use Disorder, sponsored by Friends Research Institute, Inc.. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-12.
Sponsored by Friends Research Institute, Inc. · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies testing sublocade in Opioid-Related Disorders — 2 open to participants now, 2 under way, none of them phase 3. Sublocade · Opioid-Related Disorders.
Among the 12 studies testing sublocade in Opioid-Related Disorders, this one is the 6th largest by enrollment, is one of 2 that started in 2025, is one of 3 in phase 3, and was the 12th registered.
1,476 studies on the registry are indexed under Opioid-Related Disorders; 293 are open to participants now.
Browse Opioid-Related Disorders studies →2 of the 12 studies testing sublocade in Opioid-Related Disorders are open now, in 1 country. Recruiting first, the newest first:
Lifespan · Sites in United States
Ages 18+
NYU Langone Health · Sites in United States
Men only
By country, each count listing its studies:
Sublocade: first FDA approval 2017 (SUBLOCADE), first EMA approval 2006. What it is approved for, and how studies give it, is on its page →
Of the 213 Opioid-Related Disorders studies recruiting now, 123 (58%) set no upper age limit and 76 (36%) stop at 75 or younger; 14 take children under 18; 53 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 4 · Phase 3 4 · Phase 4 5
First in 2019; this study’s year is marked. 2 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 23 is below the median of 63 across 1,170 interventional studies indexed under Opioid-Related Disorders.
Median enrollment 21 across the 12 interventional studies. Of the 7 that completed or were terminated, 5 (71%) have results posted.
This tab as a report to print or save as PDF → With an account.
2 of 12 have an industry lead sponsor. The 9 most frequent:
Friends Research Institute, Inc. is the lead sponsor of 45 studies on the registry; 5 are open to participants now.
20 studies in Opioid-Related Disorders by Friends Research Institute, Inc.: 4 open now, 7 under way, 3 of them phase 3. Of 13 finished, 5 (38%) have results posted.
Among the 20 studies in Opioid-Related Disorders by Friends Research Institute, Inc., this one is the 17th largest by enrollment, is one of 5 that started in 2025, is one of 4 in phase 3, and was the 19th registered.
Friends Research Institute, Inc.’s Opioid-Related Disorders studies by the year they started, since 2008.
2 of the studies testing sublocade in Opioid-Related Disorders that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06051890NYU Langone HealthAssessing Optimal XRB Initiation Points in Jail | 2026-12-01 |
| NCT06880718LifespanInjectable Buprenorphine in Prison: A Preference Trial | 2027-01 |
Add all 2 to your calendar (.ics) → With an account.
Among the 12 studies testing sublocade in Opioid-Related Disorders, from their registry updates:
Among Friends Research Institute, Inc.’s 20 in Opioid-Related Disorders:
This tab as a report to print or save as PDF → With an account.
This study is an open label pilot study of 30 incarcerated men and women receiving sublingual buprenorphine (SL-B) in jail who will voluntarily switch to extended-release buprenorphine (BRIXADI) using telemedicine prior to release. Individuals will receive weekly XR-B and at least one monthly XR-B injection prior to release. Individuals will be linked to a community treatment provider where they will continue their treatment (buprenorphine) post-release. Participants will be assessed at 1,2-, and 3-months post release
This study is an open label pilot study of 30 incarcerated men and women receiving sublingual buprenorphine (SL-B) in jail who will voluntarily switch to extended-release buprenorphine (BRIXADI) using telemedicine prior to release. Individuals will receive weekly XR-B and at least one monthly XR-B injection prior to release. Individuals will be linked to a community treatment provider where they will continue their treatment (buprenorphine) post-release. Participants will be assessed at 1,2-, and 3-months post release.1) To determine the feasibility and willingness of individuals in jail to transition from telemedicine SL-B to XR-B and continue upon release in the community.
2) To examine (a) pharmacotherapy adherence pre release and community injections received), b) illicit opioid urine test results; (c) self-reported illicit opioid use; d) re-arrest and reincarceration; e) non-fatal and fatal overdose.
3) Explore barriers and facilitators to telemedicine XR-B implementation in jail: (1) telemedicine XR-B administration; (2) telemedicine staffing (both custody and medical); and (2) continuity of care after release to a community provider
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
extended-release buprenorphine
Drug: Extended Release Buprenorphine
extended-release buprenorphine using telemedicine in jail
medication adherence
number of extended-release buprenorphine injections completed
Time frame: three months post-release
illicit opioid use
Illicit opioid use days using the Timeline Follow-Back (TLFB)
Time frame: three months post-release
Urine toxicology
urine toxicology rapid test for illicit opioids
Time frame: three months post-release
overdose
Opioid Overdose times non-fatal
Time frame: three months post-release
Plan to share: No — Need additional information.
No publications or documents are linked to this record.
Ran from Jun 2025 to primary completion in Jun 2026, 12 months.
Of 31 phase 3 interventional studies under Opioid-Related Disorders, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 56. This study's 12 months is below that.
Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 12, 2026: primary completion Jul 2026 → Jun 2026 and completion Sep 2026 → Aug 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Sublocade
Friends Research Institute, Inc.